Jenny Donovan

Generating author description...

All published works

Action	Title	Year	Authors
+	Specificity of a polygenic score for aggressive prostate cancer	2025	Anna Dornisch George Xu Roshan Karunamuni Charles A. Brunette Morgan Danowski Craig C. Teerlink J. Michael Gaziano Isla P. Garraway Richard Hauger Adam S. Kibel
+	From a genomic risk model to clinical trial implementation in a learning health system: the ProGRESS Study	2024	Jason L. Vassy Anna Dornisch Roshan Karunamuni Michael Gatzen Christopher Kachulis Niall J. Lennon Charles A. Brunette Morgan E. Danowski Richard L. Hauger Isla P. Garraway
+ PDF Chat	Additional SNPs improve the performance of a polygenic hazard score for prostate cancer	2020	Roshan Karunamuni Minh‐Phuong Huynh‐Le Chun Chieh Fan Wesley K. Thompson Rosalind A. Eeles Zsofia Kote‐Jarai Kenneth Muir Artitaya Lophatananon Johanna Schleutker Nora Pashayan
+ PDF Chat	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study	2019	Jenny Donovan Brent C. Opmeer Grace Young Nicola Mills Richard M. Martin J. Athene Lane Chris Metcalfe T. J. Peters Michael Davis Emma L. Turner
+ PDF Chat	A genetic hazard score to personalize prostate cancer screening, applied to population data	2019	Minh‐Phuong Huynh‐Le Chun Fan Roshan Karunamuni Eleanor Walsh Emma L. Turner J. Athene Lane Richard M. Martin David E. Neal Jenny Donovan Freddie C. Hamdy
+ PDF Chat	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation	2018	Leila Rooshenas Lauren J Scott Jane Blazeby Chris Rogers Kate Tilling Samantha Husbands Carmel Conefrey Nicola Mills Robert C. Stein Chris Metcalfe
+ PDF Chat	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT	2018	Freddie C. Hamdy Daisy Elliott Steffi le Conte Lucy Davies Richéal Burns Claire Thomson Richard Gray Jane Wolstenholme Jenny Donovan Ray Fitzpatrick
+ PDF Chat	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis	2018	Andrew J. Vickers Emily Vertosick Daniel D. Sjoberg Freddie C. Hamdy David E. Neal Anders Bjartell Jonas Hugosson Jenny Donovan Arnauld Villers Stephen Zappala
+ PDF Chat	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial	2017	Jenny Donovan Grace Young Eleanor Walsh Chris Metcalfe J. Athene Lane Richard M. Martin Marta Tazewell Michael Davis T. J. Peters Emma L. Turner
+	Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer	2017	Freddie C. Hamdy Jenny Donovan
+ PDF Chat	10-Year Outcomes in Localized Prostate Cancer	2017	Freddie C. Hamdy Jenny Donovan David E. Neal
+	Description of statistical methods used to model repeated measures of prostate-specific antigen	2015	Andrew J. Simpkin Leila Rooshenas Julia Wade Jenny Donovan J. Athene Lane Richard M. Martin Chris Metcalfe Peter C. Albertsen Freddie C. Hamdy Lars Holmberg
+ PDF Chat	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis	2015	Nora Pashayan Stephen W. Duffy David E. Neal Freddie C. Hamdy Jenny Donovan Richard M. Martin Patricia Harrington Sara Benlloch Ali Amin Al Olama Mitul Shah
+ PDF Chat	Misclassification of outcome in case–control studies: Methods for sensitivity analysis	2014	Rebecca Gilbert Richard M. Martin Jenny Donovan J. Athene Lane Freddie C. Hamdy David E. Neal Chris Metcalfe
+ PDF Chat	Evaluation of source data verification in a multicentre cancer trial (PROTECT)	2013	J. Athene Lane Michael Davis Liz Down Rhiannon Macefield David E. Neal Freddie C. Hamdy Jenny Donovan Hilary Taylor
+	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes	2013	Andrew J. Simpkin Chris Metcalfe Richard M. Martin J. Athene Lane Jenny Donovan Freddie C. Hamdy David E. Neal Kate Tilling
+ PDF Chat	Using adaptive designs for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests	2013	Janet Dunn Andrea Marshall Amy Campbell Nigel Stallard Claire Hulme Peter Hall Helen Higgins John M.S. Bartlett Adrienne Morgan Jenny Donovan
+ PDF Chat	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group	2012	Donna P. Ankerst Andreas Boeck Stephen J. Freedland J. Stephen Jones Angel M. Cronin Monique J. Roobol Jonas Hugosson Michael W. Kattan Eric A. Klein Freddie C. Hamdy
+ PDF Chat	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group	2011	Donna P. Ankerst Andreas Boeck Stephen J. Freedland Ian M. Thompson Angel M. Cronin Monique J. Roobol Jonas Hugosson J. Stephen Jones Michael W. Kattan Eric A. Klein
+ PDF Chat	Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial	2011	J. Athene Lane Liz Down Julia Wade David E. Neal Freddie C. Hamdy Jenny Donovan
+	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance	2011	J. Athene Lane Julia Wade Liz Down Susan Bonnington Peter Holding Teresa Lennon Amanda Jones C. Elizabeth Salter David E. Neal Freddie C. Hamdy
+	The International Society for Clinical Biostatistics annual conference, Ottawa, Canada	2011	Rebecca Gilbert Richard M. Martin J. Athene Lane Jenny Donovan Chris Metcalfe
+ PDF Chat	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group	2010	Andrew J. Vickers Angel M. Cronin Monique J. Roobol Jonas Hugosson J. Stephen Jones Michael W. Kattan Eric A. Klein Freddie C. Hamdy David E. Neal Jenny Donovan
+ PDF Chat	Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen Era	2006	Richard M. Martin David Gunnell Freddie C. Hamdy David E. Neal J. Athene Lane Jenny Donovan
+	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study)	2006	Nicola Mills Chris Metcalfe Carine Ronsmans Michael Davis J. Athene Lane Jonathan A C Sterne T. J. Peters Freddie C. Hamdy David E. Neal Jenny Donovan
+ PDF Chat	Prostate Testing for Cancer and Treatment (ProtecT) feasibility study	2003	Jenny Donovan Freddie C. Hamdy David E. Neal T. J. Peters Samuel J. Oliver Lucy Brindle David Jewell Philip Powell David Gillatt Daniel Dedman

Common Coauthors

Coauthor	Papers Together
Freddie C. Hamdy	23
David E. Neal	21
J. Athene Lane	15
Richard M. Martin	11
Chris Metcalfe	8
Emma L. Turner	6
Nicola Mills	5
T. J. Peters	4
Anders M. Dale	4
Michael Davis	4
Tyler M. Seibert	4
Monique J. Roobol	4
Ole A. Andreassen	4
Jonas Hugosson	4
Arnauld Villers	4
Rosalind A. Eeles	4
Adam S. Kibel	4
Eleanor Walsh	4
Hans Lilja	4
Andrew J. Vickers	4
Gilles Salama	3
David Gillatt	3
Angel M. Cronin	3
Peter Holding	3
Helmut Klocker	3
A. Benchikh	3
Dipen J. Parekh	3
Wolfgang Horninger	3
Christiane Maier	3
Jyotsna Batra	3
Fritz H. Schröder	3
Liz Down	3
James W.F. Catto	3
Jong Y. Park	3
Johanna Schleutker	3
Fredrik Wiklund	3
Donna P. Ankerst	3
Daniel M. Moreira	3
Kate Tilling	3
Zsofia Kote‐Jarai	3
Michael W. Kattan	3
Derek J. Rosario	3
Ruth C. Travis	3
Eric A. Klein	3
Nora Pashayan	3
Julia Wade	3
Ian G. Mills	3
Andrea Marshall	2
Prasad Bollina	2
Luke Hughes‐Davies	2

Commonly Cited References

Action	Title	Year	Authors	# of times referenced
+ PDF Chat	Prostate Testing for Cancer and Treatment (ProtecT) feasibility study	2003	Jenny Donovan Freddie C. Hamdy David E. Neal T. J. Peters Samuel J. Oliver Lucy Brindle David Jewell Philip Powell David Gillatt Daniel Dedman	3
+ PDF Chat	A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results	2015	Tessa Kennedy‐Martin Sarah L. Hulin-Curtis Douglas E. Faries Susan Robinson Joseph A. Johnston	2
+ PDF Chat	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group	2010	Andrew J. Vickers Angel M. Cronin Monique J. Roobol Jonas Hugosson J. Stephen Jones Michael W. Kattan Eric A. Klein Freddie C. Hamdy David E. Neal Jenny Donovan	2
+	Computing the Cox model for case cohort designs.	1999	Terry M. Therneau Hongzhe Li	2
+ PDF Chat	Decision Curve Analysis: A Novel Method for Evaluating Prediction Models	2006	Andrew J. Vickers Elena B. Elkin	2
+	Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach	1988	Elizabeth R. DeLong David M. DeLong Daniel L. Clarke‐Pearson	2
+	Performance of Prostate Cancer Prevention Trial Risk Calculator in a Contemporary Cohort Screened for Prostate Cancer and Diagnosed by Extended Prostate Biopsy	2009	Carvell T. Nguyen Changhong Yu Ayman Moussa Michael W. Kattan J. Stephen Jones	2
+	Regression Shrinkage and Selection Via the Lasso	1996	Robert Tibshirani	2
+	1873: External Validation of the Prostate Cancer Prevention Trial Risk Calculator in a Screened Population	2007	Dipen J. Parekh Amanda Beth Reed Donna P. Ankerst Betsy Higgins Javier Hernández Edith Canby‐Hagino Timothy C. Brand Dean A. Troyer Robin J. Leach Ian M. Thompson	2
+	THE LASSO METHOD FOR VARIABLE SELECTION IN THE COX MODEL	1997	Robert Tibshirani	2
+ PDF Chat	Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication	2010	Andrew J. Vickers Angel M. Cronin Monique J. Roobol Caroline Savage Mari Peltola Kim Pettersson Peter T. Scardino Fritz H. Schröder Hans Lilja	2
+	Multiple imputation of discrete and continuous data by fully conditional specification	2007	Stef van Buuren	2
+	Variations in PSA doubling time in patients with prostate cancer on “watchful waiting”: Value of short-term PSADT determinations	2004	Phillip Ross Salaheddin M. Mahmud Andrew J. Stephenson Luís Souhami Simon Tanguay Armen Aprikian	1
+	A two‐stage trial design for testing treatment, self‐selection and treatment preference effects	1989	Gerta Rücker	1
+	A New Design for Randomized Clinical Trials	1979	Marvin Zelen	1
+ PDF Chat	Linear Mixed Models for Longitudinal Data	1997	Geert Verbeke	1
+	Watchful Waiting and Factors Predictive of Secondary Treatment of Localized Prostate Cancer	2004	Hongyan Wu Leon Sun Judd W. Moul HONGYU WU David G. McLeod Christopher L. Amling Raymond Lance Leo Kusuda Timothy F. Donahue John Foley	1
+ PDF Chat	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group	2011	Donna P. Ankerst Andreas Boeck Stephen J. Freedland Ian M. Thompson Angel M. Cronin Monique J. Roobol Jonas Hugosson J. Stephen Jones Michael W. Kattan Eric A. Klein	1
+ PDF Chat	Sensitivity analysis for misclassification in logistic regression via likelihood methods and predictive value weighting	2010	Robert H. Lyles Ji Lin	1
+ PDF Chat	Management and Conduct of Randomized Controlled Trials	2002	Genell L. Knatterud	1
+	Predictors of Treatment After Initial Surveillance in Men With Prostate Cancer: Results From CaPSURE	2003	Maxwell V. Meng Eric P. Elkin Susan R. Harlan S. Mehta Deborah P. Lubeck Peter R. Carroll	1
+	Active Surveillance with Selective Delayed Intervention: A Biologically Nuanced Approach to Favorable-Risk Prostate Cancer	2003	Laurence Klotz	1
+ PDF Chat	Logistic Regression When the Outcome Is Measured with Uncertainty	1997	Laurence S. Magder James P. Hughes	1
+	Can Prostate Specific Antigen Derivatives and Pathological Parameters Predict Significant Change in Expectant Management Criteria for Prostate Cancer?	2003	Masood A. Khan H. Ballentine Carter Jonathan I. Epstein Michael Craig Miller Patricia Landis Patrick Walsh Alan W. Partin Robert W. Veltri	1
+	Nonlocal Behavior in Polynomial Regressions	1998	Lonnie Magee	1
+	Patterns of bias due to differential misclassification by case–control status in a case–control study	2007	Po‐Huang Chyou	1
+	Quality assurance for interventions in clinical trials: Multicenter data monitoring, data management, and analysis	1994	Brad H. Pollock	1
+	Robust Locally Weighted Regression and Smoothing Scatterplots	1979	William S. Cleveland	1
+	Research staff turnover and participant adherence in the Women's Health Initiative	2003	Marie Jackson Nancy Berman Margaret Huber Linda Snetselaar Iris Granek Kathryn Boe Carole Milas Jill Spivak Rowan T. Chlebowski	1
+ PDF Chat	Using fractional polynomials to model non‐linear trends in longitudinal data	2009	Jeffrey D. Long Ji Hoon Ryoo	1
+	The Comparability of Models for Predicting the Risk of a Positive Prostate Biopsy with Prostate-Specific Antigen Alone: A Systematic Review	2008	Fritz H. Schröder Michael W. Kattan	1
+ PDF Chat	Results of Conservative Management of Clinically Localized Prostate Cancer	1994	Gerald W. Chodak Ronald A. Thisted Glenn S. Gerber Jan‐Erik Johansson Jan Adolfsson G. W. Jones G. D. Chisholm Boaz Moskovitz Pinhas M. Livne John Warner	1
+ PDF Chat	Testing for familial aggregation of functional traits	2009	Yixin Fang Yuanjia Wang	1
+	Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer.	2012	Craig Ramsay Robert Pickard Clare Robertson Andrew Close Luke Vale Nigel Armstrong Daniel A. Barocas CG Eden Cynthia Fraser Tara Gurung	1
+	Developing systems for cost-effective auditing of clinical trials	1997	Robert M. Califf Sharon L. Karnash Lynn H. Woodlief	1
+	Expectant management as an option for men with stage T1c prostate cancer: a preliminary study	1997	James L. Mohler Bernadette T. Williams John A. Freeman James L. Mohler	1
+	Sensitivity Analysis of Misclassification: A Graphical and a Bayesian Approach	2006	Haitao Chu Zhaojie Wang Stephen R. Cole Sander Greenland	1
+	Modeling Prostate Specific Antigen Kinetics in Patients on Active Surveillance	2006	Liying Zhang Andrew Loblaw Laurence Klotz	1
+ PDF Chat	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis	2015	Nora Pashayan Stephen W. Duffy David E. Neal Freddie C. Hamdy Jenny Donovan Richard M. Martin Patricia Harrington Sara Benlloch Ali Amin Al Olama Mitul Shah	1
+ PDF Chat	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study	2009	Chris Metcalfe Kate Tilling Mark Davis J. Athene Lane Richard M. Martin Howard Kynaston Philip Powell David E. Neal Freddie C. Hamdy J L Donovan	1
+	Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials	2009	Oana Brosteanu Peggy Houben Kristina Ihrig Christian Ohmann Ursula Paulus Beate Pfistner G. Schwarz Anke Strenge-Hesse Ulrike Zettelmeyer	1
+	Random-Effects Models for Longitudinal Data	1982	Nan M. Laird James H. Ware	1
+ PDF Chat	The effect of misclassification on the estimation of association: a review	2005	Michael Höfler	1
+ PDF Chat	Critical analysis of prostate‐specific antigen doubling time calculation methodology	2006	Robert S. Svatek Michael J. Shulman Pankaj K. Choudhary Elie A. Benaim	1
+ PDF Chat	Understanding controlled trials: What is a patient preference trial?	1998	David Torgerson Bonnie Sibbald	1
+ PDF Chat	Applying Quantitative Bias Analysis to Epidemiologic Data	2009	Aliza K. Fink Matthew P. Fox Timothy L. Lash	1
+	RANDOMIZED AND NON-RANDOMIZED PATIENTS IN CLINICAL TRIALS: EXPERIENCES WITH COMPREHENSIVE COHORT STUDIES	1996	Claudia Schmoor Manfred Olschewski Martin Schumacher	1
+ PDF Chat	Combining longitudinal studies of PSA	2004	Lurdes Y. T. Inoue Ruth Etzioni Elizabeth H. Slate Christopher H. Morrell David F. Penson	1
+	Modelling risk when binary outcomes are subject to error	2004	Pat S. McInturff Wesley O. Johnson David Cowling Ian A. Gardner	1
+ PDF Chat	Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy	2004	Anthony V. D’Amico Ming‐Hui Chen Kimberly A. Roehl William J. Catàlona	1